Welcome to our dedicated page for Scorpius Holdings news (Ticker: $NHWK), a resource for investors and traders seeking the latest updates and insights on Scorpius Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scorpius Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scorpius Holdings's position in the market.
Rhea-AI Summary
NightHawk Biosciences' Scorpius BioManufacturing subsidiary has been awarded a project to support a preclinical program for a U.S. based biotech company. The initial project value exceeds one million dollars, with the potential to exceed several million dollars over the next two years. The award reflects NightHawk's growing reputation in the industry and its track record advancing early stage clinical programs. Scorpius' specialized analytical and process development laboratories, particularly in microbial fermentation, are highlighted. NightHawk intends to expand the scope of the project as the client prepares for phase 1 clinical trials and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
-
Rhea-AI Summary
NightHawk Biosciences (NYSE American: NHWK; NHWK) changes name to Scorpius Holdings, Inc. (NYSE American: SCPX) to reflect shift into large molecule biomanufacturing CDMO. The company announced senior leadership appointments and team expansions to support growing client programs and sales pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
-
Rhea-AI Summary
NightHawk Biosciences (NHWK) announced that its subsidiary, Scorpius BioManufacturing, has begun work on a multi-million dollar contract awarded by a leading university to develop and manufacture a novel biologic targeting substance use disorder, including drug, alcohol, and opioid addiction. The CEO, Jeff Wolf, expressed excitement about the traction and growing pipeline within Scorpius, highlighting the company's expertise and dedication to customer service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
Rhea-AI Summary
NightHawk Biosciences (NYSE American: NHWK) completed a successful demonstration run for a microbial vaccine program developed by a top-tier research university, attracting considerable interest for its CDMO services. The next phase includes scaling up to cGMP manufacturing for a phase 1 infectious disease trial. NightHawk is focused on rapidly advancing biologic and cell therapy programs, offering a broad array of analytical testing, process development, and manufacturing services at its state-of-the-art facilities in San Antonio, TX.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.79%
Tags
-
Rhea-AI Summary
NightHawk Biosciences (NYSE American: NHWK) has initiated its first manufacturing run for a premier U.S.-based biopharmaceutical company in the Company’s new, state-of-the-art microbial manufacturing facility. The company expects to recognize revenue from the multi-million-dollar contract during 2024 and anticipates further expansion of the agreement's scope of work and revenue potential. NightHawk's CEO, Jeff Wolf, highlights the growing interest in the industry and the rapidly expanding sales pipeline that includes premier biopharma companies, as well as leading government and academic research institutes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.42%
Tags
-
Rhea-AI Summary
NightHawk Biosciences (NYSE American: NHWK) announced its strategic shift into a pure-play biomanufacturing Contract Development & Manufacturing Organization (CDMO), divesting non-core assets and signing over $20 million in manufacturing contracts. The company expects to eliminate over $40 million in commitments and reduce operating expenses by more than $13 million per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
Rhea-AI Summary
NHWK: NightHawk Biosciences Provides Strategic, Financial, and Operational Updates for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
-
Rhea-AI Summary
NightHawk Biosciences provides strategic, financial, and operational updates for Q2 2023. The company is progressing with biomanufacturing operations and investing in San Antonio facilities. R&D activities show promising preclinical data. Q2 2023 revenue was $0.7 million, compared to $0.05 million in Q2 2022. R&D expenses increased by 21.3% to $5.7 million. Cost of revenues was $0.4 million. Selling, general, and administrative expenses were $7.4 million. Net loss was approximately $13.9 million. The company had $18.6 million in cash, cash equivalents, and short-term investments as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Scorpius Holdings, Inc.
NYSE:NHWK
NHWK Rankings
NHWK Stock Data
14.90M
24.16M
7.33%
8.61%
1.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
US
Morrisville
About NHWK
heat biologics is a clinical-stage company focused on developing its proprietary impact™ (immune pan-antigen cytotoxic therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. heat's impact therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. impact effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. impact therapy is applicable to a wide range of cancers. heat is currently conducting two phase 2 clinical trials with its hs-110 to treat non-small cell lung cancer (nsclc) and its hs-410 to treat bladder cancer.